Cspc Pharmaceutical Group Limited · HKEX:1093
Cspc Pharmaceutical — Q1 2026 Earnings Presentation
30 slides from Cspc Pharmaceutical's earnings presentation, May 2026
Slide 1: 2026Q1 Results Presentation
NoxBseRoaa CSPC CSPC PHARMACEUTICAL GROUP LIMITED (Stock Code : 1093) 2026Q1 Results Presentation May. 2026
Slide 2: China's Leading Innovative Pharmaceutical Enterprise
ir China’s Leading Innovative Pharmaceutical Enterprise R&D Capabilities — Company’s Position and Reputation — + Chinese enterprises rank NO.448 —— The Fortune China 500 List (2025) 8 5 + Global pharmaceutical companies rank NO.48 — Pharmaceutical Manager magazine of the United States (2025) R&D pla
Slide 3: 2026Q1 Updates
2026Q1 Updates — | Major Clinical Trial Progress i | Regulatory Updates rail IND approvals: + China(14) | Overseas (7) a New drugs approved + Clevidipine Injectable Emulsion 12 New pivotal clinical trials : + Aripiprazole Injection + Anbenitamab injection (KN026) : + Amphotericin B liposomes (Europe
Slide 4: 2026 Data Read-out Plan
2026 Data Read-out Plan AACR finished sys6010 EGFR ADC Nasopharyngeal carcinoma phase | - oral ASCO accepted Anbenitamab Injection KNO26 breast cancer(Neoadjuvant) phase III — oral (LBA) ASCO accepted SYS6010 EGFR ADC Advanced solid tumor phase II - poster ASCO accepted SYS6010+SYH2051 EGFR ADC+ATM
Slide 5: SYS6043 (B7-H3 ADC) Nasopharyngeal Carcinoma Data Read-out
r SYS6043 (B7-H3 ADC) Nasopharyngeal Carcinoma Data Read-out — ICHNO Oral:Presentatien ICHNQ 2026 - 19 -21 March 2026 Seville, Spain * Topoisomerase | inhibitor , DAR ~6 Fcy receptor effector silencing design and cleavable linker 8 mg/kg Q3W (n=29) BOR, n(%) ug Design + Bystander Effect cR 0 0 12.(4
Slide 6: SYS6043 (B7-H3 ADC) Gynecological Tumor Data Read-out
SYS6043 (B7-H3 ADC) Gynecological Tumor Data Read-out — SGO Oral Presentation====m Phase | dose escalation and PK expansion Phase II Cohort expansion SYS6043 shows durable anti-tumor activity reated patients wit gynecological tumors 10.0 mg/kg, Q3W ‘ Ovarian cancer BOIN design Type of cancer ORR DCR
Slide 7: SYS6010 Single-agent Treatment for Nasopharyngeal Carcinoma
AAGR {or Cancer Resear PD ORR (95% Cl), % DCR (95% Cl), % SYS6010 Single-agent Treatment for Nasopharyngeal Carcinoma — 2026AACR r= Presentation Phase | Study Results of SYS6010 Monotherapy in Patients with Recurrent or Metastatic Advanced Nasopharyngeal Carcinoma (NPC) Progressed after Immune Check
Slide 8: Financial Highlights
Financial Highlights
Slide 9: Financial Highlights
Financial Highlights Unit: RMB’ M 1Q26 1Q25 Change Revenue’ 6,465 7,015 -7.8% Revenue (excluding the licence fee income) 6319 6,297 +0.4% Gross profit 4,268 4,705 -9.3% Gross profit margin 66.0% 67.1% -1.1 pp R&D expenses 1,403 1,302 +7.7% Reported profit attributable to shareholders of the Company
Slide 10: Revenue
r Revenue — — aa Revenue by product category Revenue by therapeutic area Unit: RMB’ M 1Q26 1Q25 Change 1026 1Q25 Change g Nervous system 2,331 1,908 +22.2% x = 1 9 ! Finished drugs = Oncology 565 552 +2.3% 1 |= Anti-infectives 838 922 -9.0% Bulk vitamin C 494 608 -18.7% Cardiovascular 538 4n +30.8%
Slide 11: Operating Profit
ir Operating Profit Unit: RMB’ M 1026 1025 Change oun poe Change Finished drugs 4,024 1,394 26.5% 19.6% 25.3% -5.7 pp Bulk vitamin C 6 98 94.1% 1.2% 16.2% -15.0 pp Bulk antibiotics 37 a1 59.4% 12.2% 19.6% -7.4pp Eunctional Foodland 36 81 55.6% 8.1% 18.4% -10.3 pp Others for two periods/years, rounde
Slide 12: R&D Pipeline
R&D Pipeline
Slide 13: R&D Overview
[gy R&D Overview R&D Centers & Projects Technology Platforms + 5 R&D centres located in + 8 national science & technology China & the U.S. qualifications + Approx. 200 Innovative drugs + 2national key labs and new formulations + 8 innovative R&D platforms Intellectual Property + 2759 patent applicat
Slide 14: Major R&D Technology Platforms
8 Major R&D Technology Platforms Nanoparticle Formulation Technology Platform >» Mitoxantrone hydrochloride liposomes > Docetaxel for injection (albumin-bound) > lrinotecan liposomes > Sirolimus for injection (albumin-bound) Antibody/Fusion Protein Technology Platform ‘ea ie > JMT203 (GFRAL) > JMT10
Slide 15: Expected Launch 2026-2028
Expected Launch 2026-2028 (In plan) Si) Vv: 3 has completed Launched 2021-2025 Anfulike Duoenda Duentai Jinlitai Mingfule (AIS) Enyitan Enshuxing Ansulike Meiluotai \ Shanzeping J Expected Launch 2026 (In plan) Clevidipine injectable emulsion vo Acute hypertension crisis Anbenitamab injection (KNO26
Slide 16: R&D pipeline — Vaccine, CAR-T
R&D pipeline — Vaccine, CAR-T = Premier mRNA Delivery Platform The world's first LNP Ex vivo CAR-T with clinical approval, and China’s first in vivo CAR-T granted clinical IND. Major candidates Target Type Treatment plan Phase | Phase ll Phase Ill Launch ( > . BA.5 Variant Incorporate for emergency
Slide 17: R&D pipeline - SiRNA Series Products
[gy R&D pipeline - SIRNA Series Products 5 assets in clinical development, leading China in both pipeline quantity and development progress. Targeted delivery to the eyes, lungs, fat, and muscles has been achieved, enabling a broader range of indications. Target Type Treatment plan Major candidates
Slide 18: R&D Pipeline — Biological Agents
R&D Pipeline — Biological Agents 4 commercialized, 6 BLA filed, 11 under pivotal trial stage -- Including various forms of drugs such as antibody drugs, cell therapies, and ADCs Launch ae Target Type Treatment plan Phase | Phasell Phaselll © NDA/BLA Monotherapy Omalizumab IgE Biosimilar Ulsinumab IL
Slide 19: R&D Pipeline — Biological Agents
R&D Pipeline — Biological Agents Major candidates Target Type Treatment plan Phase | Phase II Phase III NDA/BLA Launch Monotherapy Osteoclastoma JMT103 RANKL mAb Monotherapy vs Zoledronic acid Malignant solid tumor bone metastasis Monotherapy Platinum-resistant PD-L1 positive advanced cervical cance
Slide 20: R&D Pipeline — Biological Agents
R&D Pipeline — Biological Agents Major . Treatment plan Phase | Phase Il Phase Ill NDA/BLA Launch candidates Target Type p Monotherapy vs T-DM1 22L HER2+ breast cancer Anbenitamab Monotherapy vs Chemotherapy 2L/3L HER2 Low expression breast cancer repodatecan HER2 ADC (JSKNO03) Monotherapy vs Chemot
Slide 21: R&D Pipeline - New Formulations
R&D Pipeline - New Formulations 5 commercialized, 2 NDA filed, 5 under pivotal trial stage -- Including various forms of drugs such as liposomes, albumin and nanocrystals Major candidates Type Treatment plan Phase | Phase Il Phase lll NDA/BLA Launch Mitoxantrone hydrochloride . liposome injection Ne
Slide 22: R&D Pipeline - Small Molecule Drugs
R&D Pipeline - Small Molecule Drugs 1 commercialized, 1 NDA filed, 5 under pivotal trial stage Major candidates Target Type Treatment plan Phase | Phase Il Phase Ill NDA/BLA Launch Monotherapy Recurrent or progressive high-grade meningioma SYHA1813 VEGFRICSF1R Small molecule Monotherapy Adjuvant the
Slide 23: Common Generics Launch Plan
Common Generics Launch Plan projects are currently in the pharmaceutical research phase. 20+ generic drugs are expected to be launched during the years 2026-2027; Additionally, approximately 1 0 2027 2026 coe Tandospirone citrate Iron sucrose injection tablets Others Mental nerve Esomeprazole magnes
Slide 24: ESG
ESG
Slide 25: Building a Sustainable Business, Aim to Become an ESG Leader
Building a Sustainable Business, Aim to Become an ESG Leader in — Pharmaceutical Industry Received MSCI ESG Rating of A for 5 2025 Key Environmental Protection Data consecutive years *The emission reduction target is based on the emission in 2017 Greenhouse gas emissions Total energy consumption per
Slide 26: Appendix: Product Overview
Appendix: Product Overview
Slide 27: Business Development Drives Global Expansion
r Business Development Drives Global Expansion In 2025, 4 BD transactions have been completed. aA A P . A - S 18.5 billion US dollars — The largest-ever licensing The total licence fee is 9.71 billion US dollars , including 260 milion US dollars upfront payment. deal by a Chinese pharmaceutical comp
Slide 28: Finished Drugs Overview by Therapeutic Areas
Finished Drugs Overview by Therapeutic Areas Nervous + Major products: NBP, Mingfule-AlS (recombinant human TNK tissue-type plasminogen activator system for injection), Shuanling, Enliwei (lacosamide injection, lacosamide tablets), Enxi (Pramipexole Dihydrochloride Tablets), Oushuan (paliperidone Ex
Slide 29: Innovation achievements: Overview of Key products
Innovation achievements: Overview of Key products — New Formulations and Innovative drugs Biosimilar Drugs oe -- -------------- Re Saale aati taal tatatatatatatatal Sy ’ Doatd \ i : bf fj rl -— 4 ; 5 Ea . Jnyoul Fi ae H J & po 1 ' \ f i H i Butylphthalide soft Recombinant human TNK PEG-rhG-CSF ' | D
Slide 30: E-mail Address of CSPC IR Team
E-mail Address of CSPC IR Team: ir@cspc.cn SUPPORT GUIDANCE 7 IR official website: “EaRyGA
CSPC Pharmaceutical Group — Q1 2026 Earnings Presentation on 6ix